报告题目：Applications of Optical Technologies in Biomedical Sciences
报告人： Dr. Eduardo H. Moriyama
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada
报告地点：化学楼HA101
报告时间：2009.9.23.（周三）上午9:30
报告简介：
Biophotonics has demonstrated its value across a wide range of biomedical applications, but is still increasing its potential as new optical concepts and corresponding instruments are developed and as the impact of these on life sciences and medicine are enhanced by converging with optical technologies coming from the molecular sciences. We have focused our research in two major areas of biophotonics: optical molecular imaging and photodynamic therapy. I will present a summary on the progress in these two fields at the Ontario Cancer Institute. A brief description is described below
Optical molecular imaging can monitor molecular events in real time and non- or minimally invasively. These core hardware and software technologies converge with emerging genomic and proteomic technologies, through the development of imaging contrast agents that can respond to specific transcription factors, initiating and controlling the expression of reporter genes, while novel tumor-targeting probes extend these into specific imaging and combination imaging/therapeutic approaches. These capabilities can accelerate the development of new therapies, particularly in preclinical evaluations of biodistribution, efficacy, toxicity and genetic/molecular/metabolic mechanisms of action.
Photodynamic therapy (PDT) is a promising modality for the treatment of cancerous and non-cancerous lesions that combines a photosensitizing agent, which is selectively accumulated in targeted tissues with its subsequent activation by light to produce cytotoxic reactive oxygen species. This triggers a cascade of molecular/cellular events leading to cell death. To date, PDT has been approved in several countries for the treatment of malignant and non-malignant diseases. We have focused on studying the PDT mechanisms leading to tumor cell death, and the design and testing of new approaches to improve tumor targeting and response.